Chronic Idiopathic Constipation (CIC) Drugs Market Overview
The Chronic Idiopathic Constipation (CIC) Drugs Market was valued at USD 4.93 Billion in 2025 and is projected to reach USD 7.97 Billion by 2032, growing at a CAGR of 7.1% during 2026–2032, with North America holding the largest share.
Primary Drivers
- Rising global prevalence of CIC, driven by aging populations, sedentary lifestyles and dietary patterns, is expanding the diagnosed and treated patient pool.
- Growing physician and patient preference for prescription prosecretory and prokinetic agents over long-term laxative use is driving therapy switching.
- Active pipeline development of novel mechanisms (guanylate cyclase-C agonists, chloride channel activators) is expanding treatment options and market value.
Primary Challenges
- Patent expiries on key branded CIC therapies are exposing the market to generic erosion and pricing pressure.
- Side-effect profiles including diarrhea and gastrointestinal discomfort associated with several drug classes limit patient compliance and persistence.
- Underdiagnosis and continued reliance on low-cost over-the-counter laxatives in many markets restrain prescription drug penetration.
This report includes a dedicated chapter covering supply chain exposure, export controls, sanctions risk, and regulatory shifts affecting Chronic Idiopathic Constipation (CIC) Drugs Market.
Chronic Idiopathic Constipation (CIC) Drugs Market Strategic Outlook
Global Chronic Idiopathic Constipation (CIC) Drugs Market is estimated to grow at a CAGR of 6.6% between 2024 and 2030.If the constipation happens chronically with an unidentifiable cause it is known as Chronic Idiopathic Constipation (CIC). The word "Idiopathic" means the cause is not known. Increasing awareness and widespread presence of idiopathic constipation are the key factors for growth of CIC drugs market. Currently CIC drugs market has huge opportunity for research and development.
Growth trajectory, 2026–2032
How this market is covered
Revenue split by type
Revenue by end use
Depending on type of drugs, global CIC drugs market is segmented into Lubiprostone, Linaclotide and others. Currently Lubiprostone drug segment dominates the market. But, due to its lower efficacy in comparison with others, patent loss and growing competition from Linaclotide, Lubiprostone will lose its dominance in the upcoming future. Depending on prescription types it is subdivided into prescribed drugs and over the counter drugs. After analysing the symptoms also, constipation is not considered as a disease but a condition, side effect or syndrome.
Usually patients avoid to visit doctors to address the issue. Therefore approximately 65% of the CIC drugs market is covered by over the counter drugs. The top players of CIC drugs market are Actavis, Chugai Pharmaceutical, Ferring International Center S.A., Synergy Pharmaceuticals, Pfizer, GlaxoSmithKline, Roche Holding AG, Sanofi, Bayer AG, Salix Pharmaceuticals Ltd, Sucampo Pharmaceuticals Inc, Ironwood Pharmaceuticals and Progenics Pharmaceuticals.
Geographically, Global Chronic Idiopathic Constipation (CIC) Drugs Market is divided into several regions such as North America, Europe, China, Japan, Southeast Asia and India. In upcoming years, North America is expected to dominate the CIC drug market. In North America approximately 28% of population suffers from chronic idiopathic constipation.
Also Government in this region is taking steps to medicate and to develop the healthcare sectors by providing advance technological and developed medication treatments support. These are major factors for growth of CIC market in North America. It is anticipated that growing awareness in developing Asian countries like China and India will create significant growth in the Asia Pacific market.
Chronic Idiopathic Constipation (CIC) Drugs Market: Product Type
- Lubiprostone
- Linaclotide
Chronic Idiopathic Constipation (CIC) Drugs Market: End Users/Application Analysis
- Hospitals & Clinics
- Ambulatory Surgical Centres
- Long Term Care Centres
Chronic Idiopathic Constipation (CIC) Drugs Market : Competitive Analysis
Report includes accurate analysis of key players with Market Value, Company profile, SWOT analysis. The Study consists of following key players in Chronic Idiopathic Constipation (CIC) Drugs Market :
- Actavis
- Chugai Pharmaceutical
- Ferring International Center S.A.
- Synergy Pharmaceuticals
- Pfizer
- GlaxoSmithKline
- Roche Holding AG
- Sanofi
- Bayer AG
- Salix Pharmaceuticals Ltd
- Sucampo Pharmaceuticals Inc
- Ironwood Pharmaceuticals
- Progenics Pharmaceuticals
Geographical analysis of Chronic Idiopathic Constipation (CIC) Drugs Market:
-
North America
- U.S.A
- Canada
- Europe
- France
- Germany
- Spain
- UK
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South East Asia
- Latin America
- Brazil
- Middle East and Africa
Pharmaceuticals Landscape
Report Coverage
| Parameter | Details |
|---|---|
| Base Year | 2025 |
| Historical Data | 2020 – 2025 |
| Forecast Period | 2026 – 2032 |
| Base Year Value | USD 4.93 Billion |
| Forecast Value | USD 7.97 Billion |
| CAGR | 7.1% |
| Regional Scope | North America · Europe · Asia-Pacific · Latin America · MEA · RoW |
Frequently Asked Questions
Chronic Idiopathic Constipation (CIC) Drugs Market was valued at USD 4.93 Billion in 2025 and is estimated to reach USD 7.97 Billion by 2032.
Chronic Idiopathic Constipation (CIC) Drugs Market is projected to grow at a CAGR of 7.1% during 2025–2032.
Chronic Idiopathic Constipation (CIC) Drugs Market is dominated by the Hospitals & Clinics segment and the North America region holds the highest market share in 2025.
Some of the top key players in the Chronic Idiopathic Constipation (CIC) Drugs Market are Actavis, Chugai Pharmaceutical, Ferring International Center S.A., Synergy Pharmaceuticals, Pfizer, GlaxoSmithKline, Roche Holding AG, Sanofi, Bayer AG, Salix Pharmaceuticals Ltd, Sucampo Pharmaceuticals Inc
1. Rising global prevalence of CIC, driven by aging populations, sedentary lifestyles and dietary patterns, is expanding the diagnosed and treated patient pool. 2. Growing physician and patient preference for prescription prosecretory and prokinetic agents over long-term laxative use is driving therapy switching. 3. Active pipeline development of novel mechanisms (guanylate cyclase-C agonists, chloride channel activators) is expanding treatment options and market value.
Yes. The report includes a dedicated section on geopolitical risk factors and their impact on supply chains, pricing, and regional demand dynamics.